Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2014

01-11-2014 | Brief Report

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer

Authors: Rebecca Roylance, David Endesfelder, Mariam Jamal-Hanjani, Rebecca A. Burrell, Patricia Gorman, Jil Sander, Niamh Murphy, Nicolai Juul Birkbak, Andrew M. Hanby, Valerie Speirs, Stephen R. D. Johnston, Maik Kschischo, Charles Swanton

Published in: Breast Cancer Research and Treatment | Issue 1/2014

Login to get access

Abstract

Regulators of transition through mitosis such as SURVIVIN and Aurora kinase A (AURKA) have been previously implicated in the initiation of chromosomal instability (CIN), a driver of intratumour heterogeneity. We investigate the relationship between protein expression of these genes and directly quantified CIN, and their prognostic utility in breast cancer. The expression of SURVIVIN and AURKA was determined by immunohistochemistry in a cohort of 426 patients with primary breast cancer. The association between protein expression and histopathological characteristics, clinical outcome and CIN status, as determined by centromeric FISH and defined by modal centromere deviation, was analysed. Significantly poorer clinical outcome was observed in patients with high AURKA expression levels. Expression of SURVIVIN was elevated in ER-negative relative to ER-positive breast cancer. Both AURKA and SURVIVIN increased expression were significantly associated with breast cancer grade. There was a significant association between increased CIN and both increased AURKA and SURVIVIN expression. AURKA gene amplification was also associated with increased CIN. To our knowledge this is the largest study assessing CIN status in parallel with the expression of the mitotic regulators AURKA and SURVIVIN. These data suggest that elevated expression of AURKA and SURVIVIN, together with AURKA gene amplification, are associated with increased CIN in breast cancer, and may be used as a proxy for CIN in breast cancer samples in the absence of more advanced molecular measurements.
Appendix
Available only for authorised users
Literature
3.
go back to reference Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101(23):8699–8704PubMedCrossRefPubMedCentral Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101(23):8699–8704PubMedCrossRefPubMedCentral
4.
go back to reference Lingle WL, Barrett SL, Negron VC, D’Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99(4):1978–1983PubMedCrossRefPubMedCentral Lingle WL, Barrett SL, Negron VC, D’Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99(4):1978–1983PubMedCrossRefPubMedCentral
5.
go back to reference Farabegoli F, Santini D, Ceccarelli C, Taffurelli M, Marrano D, Baldini N (2001) Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry 46(1):50–56PubMedCrossRef Farabegoli F, Santini D, Ceccarelli C, Taffurelli M, Marrano D, Baldini N (2001) Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry 46(1):50–56PubMedCrossRef
6.
go back to reference Fiegl M, Kaufmann H, Zojer N, Schuster R, Wiener H, Mullauer L, Roka S, Huber H, Drach J (2000) Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Pathol 31(4):448–455PubMedCrossRef Fiegl M, Kaufmann H, Zojer N, Schuster R, Wiener H, Mullauer L, Roka S, Huber H, Drach J (2000) Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Pathol 31(4):448–455PubMedCrossRef
7.
go back to reference Takami S, Kawasome C, Kinoshita M, Koyama H, Noguchi S (2001) Chromosomal instability detected by fluorescence in situ hybridization in Japanese breast cancer patients. Clin Chim Acta 308(1–2):127–131PubMedCrossRef Takami S, Kawasome C, Kinoshita M, Koyama H, Noguchi S (2001) Chromosomal instability detected by fluorescence in situ hybridization in Japanese breast cancer patients. Clin Chim Acta 308(1–2):127–131PubMedCrossRef
9.
go back to reference Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22(12):2934–2947PubMedCrossRefPubMedCentral Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22(12):2934–2947PubMedCrossRefPubMedCentral
13.
go back to reference Meraldi P, Honda R, Nigg EA (2004) Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 14(1):29–36PubMedCrossRef Meraldi P, Honda R, Nigg EA (2004) Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 14(1):29–36PubMedCrossRef
14.
go back to reference Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20(2):189–193PubMedCrossRef Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20(2):189–193PubMedCrossRef
15.
go back to reference Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3(1):51–62PubMedCrossRef Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3(1):51–62PubMedCrossRef
16.
go back to reference Sen S, Zhou H, White RA (1997) A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14(18):2195–2200PubMedCrossRef Sen S, Zhou H, White RA (1997) A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14(18):2195–2200PubMedCrossRef
18.
go back to reference Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Shimomura K, Nakamura Y, Inazawa J, Abe T, Yamagishi H (2001) Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84(6):824–831PubMedCrossRefPubMedCentral Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Shimomura K, Nakamura Y, Inazawa J, Abe T, Yamagishi H (2001) Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84(6):824–831PubMedCrossRefPubMedCentral
19.
go back to reference Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92(3):370–373PubMedCrossRef Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92(3):370–373PubMedCrossRef
21.
go back to reference Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S (2009) Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 11(5):418–425PubMedPubMedCentral Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S (2009) Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 11(5):418–425PubMedPubMedCentral
22.
go back to reference Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1(8):461–466PubMedCrossRef Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1(8):461–466PubMedCrossRef
23.
go back to reference Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392(6673):300–303PubMedCrossRef Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392(6673):300–303PubMedCrossRef
26.
go back to reference Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12(2):405–410PubMedCrossRef Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12(2):405–410PubMedCrossRef
27.
go back to reference Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C (2011) Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 20(10):2183–2194. doi:10.1158/1055-9965.EPI-11-0343 PubMedCrossRefPubMedCentral Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C (2011) Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 20(10):2183–2194. doi:10.​1158/​1055-9965.​EPI-11-0343 PubMedCrossRefPubMedCentral
29.
go back to reference McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184. doi:10.1093/jnci/dji237 PubMedCrossRef McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184. doi:10.​1093/​jnci/​dji237 PubMedCrossRef
30.
31.
go back to reference Youssef NS, Hewedi IH, Abd Raboh NM (2008) Immunohistochemical expression of survivin in breast carcinoma: relationship with clinicopathological parameters, proliferation and molecular classification. J Egypt Natl Canc Inst 20(4):348–357PubMed Youssef NS, Hewedi IH, Abd Raboh NM (2008) Immunohistochemical expression of survivin in breast carcinoma: relationship with clinicopathological parameters, proliferation and molecular classification. J Egypt Natl Canc Inst 20(4):348–357PubMed
32.
go back to reference Zhang H, Jin F (2010) HER-2 expression correlates with survivin in primary invasive ductal breast cancers. Asian Pac J Cancer Prev 11(5):1201–1204PubMed Zhang H, Jin F (2010) HER-2 expression correlates with survivin in primary invasive ductal breast cancers. Asian Pac J Cancer Prev 11(5):1201–1204PubMed
33.
go back to reference Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, Kamei M, Takeno S, Kawahara K (2007) Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27(4C):2803–2808PubMed Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, Kamei M, Takeno S, Kawahara K (2007) Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27(4C):2803–2808PubMed
34.
go back to reference Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17(4):597–604PubMedCrossRef Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17(4):597–604PubMedCrossRef
35.
go back to reference Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S, Hung MC (2004) STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 100(1):12–19PubMedCrossRef Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S, Hung MC (2004) STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 100(1):12–19PubMedCrossRef
36.
go back to reference Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G (2012) Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol. doi:10.1093/annonc/mdr527 Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G (2012) Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol. doi:10.​1093/​annonc/​mdr527
38.
go back to reference Du J, Du Q, Zhang Y, Sajdik C, Ruan Y, Tian XX, Fang WG (2011) Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas. Histol Histopathol 26(6):761–768PubMed Du J, Du Q, Zhang Y, Sajdik C, Ruan Y, Tian XX, Fang WG (2011) Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas. Histol Histopathol 26(6):761–768PubMed
39.
go back to reference Staff S, Isola J, Jumppanen M, Tanner M (2010) Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep 23(2):307–312PubMed Staff S, Isola J, Jumppanen M, Tanner M (2010) Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep 23(2):307–312PubMed
40.
go back to reference Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthai A, Cuesta MA, Terhaar Sive Droste JS, Craanen M, Schrock E, Ylstra B, Meijer GA (2009) Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58(1):79–89. doi:10.1136/gut.2007.143065 PubMedCrossRef Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthai A, Cuesta MA, Terhaar Sive Droste JS, Craanen M, Schrock E, Ylstra B, Meijer GA (2009) Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58(1):79–89. doi:10.​1136/​gut.​2007.​143065 PubMedCrossRef
43.
go back to reference Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13(6):1977–2000PubMedCrossRefPubMedCentral Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13(6):1977–2000PubMedCrossRefPubMedCentral
44.
go back to reference Davenport JW, Fernandes ER, Harris LD, Neale GA, Goorha R (1999) The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner. Genomics 55(1):113–117. doi:10.1006/geno.1998.5629 PubMedCrossRef Davenport JW, Fernandes ER, Harris LD, Neale GA, Goorha R (1999) The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner. Genomics 55(1):113–117. doi:10.​1006/​geno.​1998.​5629 PubMedCrossRef
45.
go back to reference Otaki M, Hatano M, Kobayashi K, Ogasawara T, Kuriyama T, Tokuhisa T (2000) Cell cycle-dependent regulation of TIAP/m-survivin expression. Biochim Biophys Acta 1493(1–2):188–194PubMedCrossRef Otaki M, Hatano M, Kobayashi K, Ogasawara T, Kuriyama T, Tokuhisa T (2000) Cell cycle-dependent regulation of TIAP/m-survivin expression. Biochim Biophys Acta 1493(1–2):188–194PubMedCrossRef
Metadata
Title
Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer
Authors
Rebecca Roylance
David Endesfelder
Mariam Jamal-Hanjani
Rebecca A. Burrell
Patricia Gorman
Jil Sander
Niamh Murphy
Nicolai Juul Birkbak
Andrew M. Hanby
Valerie Speirs
Stephen R. D. Johnston
Maik Kschischo
Charles Swanton
Publication date
01-11-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3153-x

Other articles of this Issue 1/2014

Breast Cancer Research and Treatment 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine